Comparative effectiveness of new pharmacotherapy regimens for mild COVID-19 based on symptom resolution dynamics

the treatment of COVID-19 remains a challenging issue worldwide due to the huge economic losses to society as a result of the disease's widespread prevalence, peculiarities of its course and complications of its development. The purpose of the work was comparative analysis of the effectiveness of new treatment regimens for outpatients with mild COVID-19. 64 medical charts of outpatient diseases with a mild course of COVID-19 were studied. Depending on the treatment regimen used, all patients were divided into two groups that received inhaled ACEs or antiviral therapy with the combination drug nortrelvir/ritonavir. The efficacy of each pharmacotherapeutic alternative would be determined on the basis of retrospective data for the timeframe of normalisation of clinical and laboratory parameters. A rule was established that the set of all clinical and laboratory parameters in the normal range is considered as a clinical endpoint. It was found that the use of ACC treats the disease until the rapid disappearance of clinical symptoms, especially in the first treatment, which works on its rapid therapeutic effect in the initial stages. Nirmatrelvir/ritonavir has also been shown to be effective in reducing symptoms, but its effect is incremental, reaching full relief slightly later than in ACC. Modeling of the dynamics of reaching the clinical point of elimination of all clinical symptoms indicates a pharmacoeconomic advantage of the use of ACC over nirmatrelvir/ritonavir, if the additional costs of treatment do not exceed the cost of three days of treatment.